Analytical Data
-
基因名
MLLT1
- Application
-
别名
Protein ENL. YEATS domain-containing protein 1
-
种属
Human
-
表达系统
E. coli
-
标签
GST-tag at N-terminal
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
Q03111
-
表达区间
1-559 aa
-
氨基酸序列
MDNQCTVQVRLELGHRAQLRKKPTTEGFTHDWMVFVRGPEQCDIQHFVEKVVFWLHDSFPKPRRVCKEPPYKVEESGYAGFIMPIEVHFKNKEEPRKVCFTYDLFLNLEGNPPVNHLRCEKLTFNNPTTEFRYKLLRAGGVMVMPEGADTVSRPSPDYPMLPTIPLSAFSDPKKTKPSHGSKDANKESSKTSKPHKVTKEHRERPRKDSESKSSSKELEREQAKSSKDTSRKLGEGRLPKEEKAPPPKAAFKEPKMALKETKLESTSPKGGPPPPPPPPPRASSKRPATADSPKPSAKKQKKSSSKGSRSAPGTSPRTSSSSSFSDKKPAKDKSSTRGEKVKAESEPREAKKALEVEESNSEDEASFKSESAQSSPSNSSSSSDSSSDSDFEPSQNHSQGPLRSMVEDLQSEESDEDDSSSGEEAAGKTNPGRDSRLSFSDSESDNSADSSLPSREPPPPQKPPPPNSKVSGRRSPESCSKPEKILKKGTYDKAYTDELVELHRRLMALRERNVLQQIVNLIEETGHFNVTNTTFDFDLFSLDETTVRKLQSCLEAVAT
-
分子量
88.44 kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
MLLT1 (Myeloid/Lymphoid or Mixed-Lineage Leukemia 1) is a crucial gene that plays a significant role in hematopoiesis and is associated with various types of leukemias, particularly those involving chromosomal translocations that result in fusion proteins. Researchers have identified MLLT1 as a key player in the regulation of gene expression through its interaction with transcription factors and chromatin-modifying enzymes. The dysfunction of MLLT1, often due to genetic abnormalities, can lead to aberrant hematopoietic development and contribute to the pathogenesis of acute leukemia. Consequently, MLLT1 has emerged as a potential therapeutic target, prompting extensive investigations into its protein structure and function. Studies on recombinant MLLT1 protein have focused on its molecular interactions, role in oncogenesis, and influence on cell differentiation pathways. Understanding the functional properties of MLLT1 and its associated signaling mechanisms is critical for developing targeted therapies that could mitigate MLLT1-related malignancies. These insights not only enhance our comprehension of hematological disorders but also pave the way for innovative treatment strategies that could improve patient outcomes in leukemia and related blood cancers.
